---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-400144"
form_type: "8-K"
ticker: "CGEM"
cik: "0001789972"
company_name: "Cullinan Therapeutics, Inc."
filed_at: "2026-09-24T11:15:56+00:00"
generated_at: "2026-09-24T11:35:35.543559+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# Cullinan outlines Q4 2026 data readouts for CLN-978, velinotamig, CLN-049

## Summary
- CLN-978 (CD19xCD3 TCE): multi-dose and single target dose data for SLE, RA, Sjögren's disease in December.
- Velinotamig (BCMAxCD3 TCE): Genrix Bio Phase 1 SLE multi-dose data at ACR Convergence 2026 on Nov 8, 2026.
- CLN-049 (FLT3xCD3 TCE): updated Phase 1 dose-escalation data in relapsed/refractory AML in December.
- CEO notes successful FDA meeting for CLN-049; registrational Phase 2 study planned to initiate.
- All data are from ongoing Phase 1 trials; no efficacy results disclosed yet.

## SEC filing metadata
- accession: 0001193125-26-400144
- form_type: 8-K
- ticker: CGEM
- cik: 0001789972
- company_name: Cullinan Therapeutics, Inc.
- filed_at: 2026-09-24T11:15:56+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1789972/000119312526400144/0001193125-26-400144-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1789972/000119312526400144/cgem-20260924.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-400144
- JSON: https://secwatch.observer/filing/0001193125-26-400144.json
- Plain text: https://secwatch.observer/filing/0001193125-26-400144.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.